Metformin Improves Insulin Sensitivity and Vascular Health in Youth With Type 1 Diabetes Mellitus
Authors: Petter Bjornstad, Michal Schäfer, Uyen Truong, Melanie Cree-Green, Laura Pyle, Amy Baumgartner, Yesenia Garcia Reyes, Aristides Maniatis, Sunil Nayak, R. Paul Wadwa, Lorna P. Browne, Jane E.B. Reusch, Kristen J. Nadeau
Journal: Circulation (2018)

Background: Cardiovascular disease is the leading cause of mortality in type 1 diabetes mellitus (T1DM) and relates strongly to insulin resistance (IR). Lean and obese adolescents with T1DM have marked IR. Metformin improves surrogate markers of IR in T1DM, but its effect on directly measured IR and vascular health in youth with T1DM is unclear. We hypothesized that adolescents with T1DM have impaired vascular function and that metformin improves this IR and vascular dysfunction. Methods: Adolescents with T1DM and control participants underwent magnetic resonance imaging of the ascending (AA) and descending aorta to assess pulse wave velocity, relative area change, and maximal (WSS MAX ) and time-averaged (WSS TA ) wall shear stress. Participants with T1DM also underwent assessment of carotid intima-media thickness by ultrasound, brachial distensibility by DynaPulse, fat and lean mass by dual-energy x-ray absorptiometry, fasting laboratories after overnight glycemic control, and insulin sensitivity by hyperinsulinemic-euglycemic clamp (glucose infusion rate/insulin). Adolescents with T1DM were randomized 1:1 to 3 months of 2000 mg metformin or placebo daily, after which baseline measures were repeated. Results: Forty-eight adolescents with T1DM who were 12 to 21 years of age (40% body mass index [BMI] ≥90th percentile; 56% female) and 24 nondiabetic control participants of similar age, BMI, and sex distribution were enrolled. Adolescents with T1DM demonstrated impaired aortic health compared with control participants, including elevated AA and descending aorta pulse wave velocity, reduced AA and descending aorta relative area change, and elevated AA and descending aorta WSS MAX and WSS TA . Adolescents with T1DM in the metformin versus placebo group had improved glucose infusion rate/insulin (12.2±3.2 [mg·kg −1 ·min −1 ]/μIU/μL versus −2.4±3.6 [mg·kg −1 ·min −1 ]/μIU/μL, P =0.005; 18.6±4.8 [mg·lean kg −1 ·min −1 ]/μIU/μL versus −3.4±5.6 [mg·lean kg −1 ·min −1 ]/μIU/μL, P =0.005) and reduced weight (−0.5±0.5 kg versus 1.6±0.5 kg; P =0.004), BMI (−0.2±0.15 kg/m 2 versus 0.4±0.15 kg/m 2 ; P =0.005), and fat mass (−0.7±0.3 kg versus 0.6±0.4 kg; P =0.01). Glucose infusion rate/insulin also improved in normal-weight participants (11.8±4.4 [mg·kg −1 ·min −1 ]/μIU/μL versus −4.5±4.4 [mg·kg −1 ·min −1 ]/μIU/μL, P =0.02; 17.6±6.7 [mg·lean kg −1 ·min −1 ]/μIU/μL versus −7.0±6.7 [mg·lean kg −1 ·min −1 ]/μIU/μL, P =0.02). The metformin group had reduced AA WSS MAX (−0.3±0.4 dyne/cm 2 versus 1.5±0.5 dyne/cm 2 ; P =0.03), AA pulse wave velocity (−1.1±1.20 m/s versus 4.1±1.6 m/s; P =0.04), and far-wall diastolic carotid intima-media thickness (−0.04±0.01 mm versus −0.00±0.01 mm; P =0.049) versus placebo. Conclusions: Adolescents with T1DM demonstrate IR and impaired vascular health compared with control participants. Metformin improves IR, regardless of baseline BMI, and BMI, weight, fat mass, insulin dose, and aortic and carotid health in adolescents with T1DM. Metformin may hold promise as a cardioprotective intervention in T1DM. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01808690.